LIVIVO - Search results -

Search results

Result 1 - 10 of total 66

Book ; Online: Fast Facts

Westman, Helen / Itchins, Malinda / Rapoport, Bernardo L.

Managing Immune-Related Adverse Events in Oncology

(Fast facts)

2023

Abstract: Fast Facts: Managing Immune-Related Adverse Events in Oncology, 2nd edition, provides an overview of immuno-oncology and an update on immune checkpoint inhibitors and their associated toxicities, alongside the principles of diagnosing and managing ... ...

Title variant	Managing Immune-Related Adverse Events in Oncology
Author's details	Helen Westman, Malinda Itchins, Bernardo L. Rapoport
Series title	Fast facts
Abstract	"Fast Facts: Managing Immune-Related Adverse Events in Oncology, 2nd edition, provides an overview of immuno-oncology and an update on immune checkpoint inhibitors and their associated toxicities, alongside the principles of diagnosing and managing immune-related adverse events, important nursing care considerations and a set of convenient management summaries for quick reference. As such, it is essential reading for all members of the cancer care team."--Provided by publisher.
MeSH term(s)	Immunotherapy ; Neoplasms/therapy ; Immune System Phenomena
Keywords	Cancer/Immunotherapy ; Cancer/Immunotherapy/Complications ; Immunology
Subject code	616.994061
Language	English
Size	1 online resource (139 pages) :, illustrations.
Edition	Second edition.
Publisher	S. Karger Publishers Ltd
Publishing place	Abingdon, Oxford
Document type	Book ; Online
Note	Includes index. ; R2 Digital Library does not include index.
ISBN	3-318-07271-0 ; 3-318-07247-8 ; 978-3-318-07247-1 ; 978-3-318-07271-6
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book ; Online: Fast Facts: Managing immune-related Adverse Events in Oncology

Rapoport, Bernardo L.

Early recognition, prompt intervention, effective management

2019

Abstract: Immunotherapeutic products, and immune checkpoints inhibitors in particular, are increasingly used in the management of malignancies, both as monotherapies and in combination. Adverse events tend to be mild to moderate, but they can be severe or even ... ...

Title variant	Fast Facts
Author's details	Bernardo L. Rapoport, Helen Westman
Abstract	Immunotherapeutic products, and immune checkpoints inhibitors in particular, are increasingly used in the management of malignancies, both as monotherapies and in combination. Adverse events tend to be mild to moderate, but they can be severe or even life-threatening. Prompt recognition and effective management are vital. 'Fast Facts: Managing Immune-Related Adverse Events' is an accessible overview that brings together clear explanations and management summaries. This highly readable handbook examines the possible effects of immunotherapies on the skin, gastrointestinal tract, liver, endocrine system and lungs, as well as less frequent reactions. Detailed descriptions and evidence-based guidance for practical application make 'Fast Facts: Managing Immunotherapy-Related Adverse Events' an invaluable resource for all healthcare professionals who may encounter patients using immunotherapy, including nurses, who are particularly well placed to identify changes linked to use of immunotherapy, those working in the emergency department and primary care providers. Table of Contents: • Immunotherapy and its side effects: an overview • Gastrointestinal and hepatic adverse events • Dermatologic adverse • Endocrine-related adverse events • Pulmonary adverse events • Less frequent adverse events • Optimizing patient care and early recognition of immune-related adverse events • Management summaries
Keywords	Oncology ; Chemotherapy
Language	English
Size	1 online resource (104 pages) : , 9 figures, 9 in color, 29 tables
Publisher	S. Karger
Publishing place	Basel
Document type	Book ; Online
ISBN	1-912776-40-5 ; 1-912776-39-1 ; 978-1-912776-40-5 ; 978-1-912776-39-9
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book ; Online: Manejo de eventos adversos relacionados con el sistema inmunitario en oncología

Rapoport, Bernardo L. / Westman, Helen

reconocimiento temprano, intervención rápida, manejo efectivo

(Fast facts)

2020

Author's details	Bernardo L. Rapoport y Helen Westman
Series title	Fast facts
Keywords	Immunology
Subject code	616.079
Language	Spanish
Size	1 online resource (120 pages).
Publisher	S. Karger Publishers Ltd
Publishing place	Abingdon, Oxford, England
Document type	Book ; Online
Note	Includes index.
ISBN	3-318-06636-2 ; 3-318-06635-4 ; 978-3-318-06636-4 ; 978-3-318-06635-7
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book ; Online: Fast Facts : Comprehensive Genomic Profiling

Rapoport, Bernardo L. / Troncone, Giancarlo / Schmitt, Fernando / Nayler, Simon J.

Making precision medicine possible

2020

Abstract: Cancer is a multifaceted disease in which genetic changes induce uncontrolled tumor growth. Genomic characterization of cancer is now leading to better diagnostic, prognostic and predictive biomarkers, and effective individualized management. 'Fast Facts: ...

Title variant	Comprehensive Genomic Profiling
Author's details	Bernardo L. Rapoport, Giancarlo Troncone, Fernando Schmitt, Simon Nayler
Abstract	Cancer is a multifaceted disease in which genetic changes induce uncontrolled tumor growth. Genomic characterization of cancer is now leading to better diagnostic, prognostic and predictive biomarkers, and effective individualized management. 'Fast Facts: Comprehensive Genomic Profiling' provides a crash course in the science, methods and application of genomic profiling. Assuming only the most basic knowledge – or memory – of cell biology, the authors provide an overview of DNA and RNA biology and next-generation sequencing. This sets in context the descriptions of prognostic and predictive biomarkers for different cancer types and genomic-based treatments. Finally, but importantly, some of the practicalities of gaining and interpreting genomic information are described. Whether you need a primer or a refresher, this short colorful book demystifies this complex subject. Contents: • Genetic mutations and biomarkers • Understanding next-generation sequencing • Elements of comprehensive genomic profiles • Role in precision oncology • Predictive and prognostic biomarkers • Overcoming barriers to genotype-directed therapy
MeSH term(s)	Neoplasms/genetics. ; DNA Fingerprinting/methods.
Keywords	Oncology ; Biochemical markers
Language	English
Size	1 online resource (108 pages) :, 17 figures, 17 in color, 13 tables
Publisher	S. Karger
Publishing place	Basel
Document type	Book ; Online
ISBN	3-318-06819-5 ; 3-318-06818-7 ; 978-3-318-06819-1 ; 978-3-318-06818-4
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Strategies to optimize the promise of checkpoint-targeted anti-cancer therapy.

Rapoport, Bernardo L / Anderson, Ronald

Immunotherapy

2024

Language	English
Publishing date	2024-05-08
Publishing country	England
Document type	Editorial
ZDB-ID	2495964-9
ISSN	1750-7448 ; 1750-743X
ISSN (online)	1750-7448
ISSN	1750-743X
DOI	10.1080/1750743X.2024.2343271
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management.

Rapoport, Bernardo L

Frontiers in pharmacology

2017 Volume 8, Page(s) 19

Abstract: Even when chemotherapy-induced nausea and vomiting (CINV) can be effectively controlled in the acute phase, it may still occur in the delayed phase. Identifying at-risk patients is complex and requires consideration of clinical, personal, demographic, ... ...

Abstract	Even when chemotherapy-induced nausea and vomiting (CINV) can be effectively controlled in the acute phase, it may still occur in the delayed phase. Identifying at-risk patients is complex and requires consideration of clinical, personal, demographic, and behavioral factors. Delayed CINV has a significant detrimental effect on patients' daily life and is responsible for significant healthcare resource utilization. Patients who do not experience acute CINV are not necessarily exempt from delayed CINV, and healthcare professionals have been shown to underestimate the incidence of delayed CINV. Failure to protect against CINV during the first cycle of chemotherapy is the most significant independent risk factor for delayed CINV during subsequent cycles. Addition of a neurokinin-1 receptor antagonist to antiemetic prophylactic regimens involving a 5-hydroxytryptamine type 3 receptor antagonist and a corticosteroid helps to ameliorate delayed CINV, particularly vomiting. Netupitant and rolapitant are second-generation neurokinin-1 receptor antagonists that provide effective prophylaxis against delayed chemotherapy-induced vomiting and also have an antinausea benefit. All of the neurokinin-1 receptor antagonists with the exception of rolapitant inhibit or induce cytochrome P450 3A4 (CYP3A4), and a reduced dose of dexamethasone (a CYP3A4 substrate) should be administered with aprepitant or netupitant; by contrast, this is not necessary with rolapitant. Here we review specific challenges associated with delayed CINV, its pathophysiology, epidemiology, treatment, and outcomes relative to acute CINV, and its management within the larger context of overall CINV.
Language	English
Publishing date	2017-01-30
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2587355-6
ISSN	1663-9812
ISSN	1663-9812
DOI	10.3389/fphar.2017.00019
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Pro-Tumorigenic and Thrombotic Activities of Platelets in Lung Cancer.

Anderson, Ronald / Rapoport, Bernardo L / Steel, Helen C / Theron, Annette J

International journal of molecular sciences

2023 Volume 24, Issue 15

Abstract: Aside from their key protective roles in hemostasis and innate immunity, platelets are now recognized as having multifaceted, adverse roles in the pathogenesis, progression and outcome of many types of human malignancy. The most consistent and compelling ...

Abstract	Aside from their key protective roles in hemostasis and innate immunity, platelets are now recognized as having multifaceted, adverse roles in the pathogenesis, progression and outcome of many types of human malignancy. The most consistent and compelling evidence in this context has been derived from the notable association of elevated circulating platelet counts with the onset and prognosis of various human malignancies, particularly lung cancer, which represents the primary focus of the current review. Key topics include an overview of the association of lung cancer with the circulating platelet count, as well as the mechanisms of platelet-mediated, pro-tumorigenic immunosuppression, particularly the role of transforming growth factor beta 1. These issues are followed by a discussion regarding the pro-tumorigenic role of platelet-derived microparticles (PMPs), the most abundant type of microparticles (MPs) in human blood. In this context, the presence of increased levels of PMPs in the blood of lung cancer patients has been associated with tumor growth, invasion, angiogenesis and metastasis, which correlate with disease progression and decreased survival times. The final section of the review addresses, firstly, the role of cancer-related platelet activation and thrombosis in the pathogenesis of secondary cardiovascular disorders and the associated mortality, particularly in lung cancer, which is second only to disease progression; secondly, the review addresses the potential role of antiplatelet agents in the adjunctive therapy of cancer.
MeSH term(s)	Humans ; Blood Platelets/metabolism ; Cell-Derived Microparticles/metabolism ; Thrombosis/metabolism ; Lung Neoplasms/metabolism ; Carcinogenesis/metabolism ; Disease Progression
Language	English
Publishing date	2023-07-25
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms241511927
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting.

Rapoport, Bernardo L

Reviews on recent clinical trials

2017 Volume 12, Issue 3, Page(s) 193–201

Abstract: Background: Nausea and vomiting are among the most feared side effects of chemotherapy and can prevent cancer patients from completing their treatment regimens. Rolapitant is a highly selective neurokinin-1 (NK-1) receptor antagonist with very good oral ...

Abstract	Background: Nausea and vomiting are among the most feared side effects of chemotherapy and can prevent cancer patients from completing their treatment regimens. Rolapitant is a highly selective neurokinin-1 (NK-1) receptor antagonist with very good oral activity, central nervous system penetration and a long (180-hour) plasma half-life. Unlike other available NK-1 receptor antagonists, rolapitant does not inhibit or induce cytochrome P450 (CYP) 3A4. Methods: Findings from recent phase II and III clinical trials of rolapitant in patients receiving highly or moderately emetogenic chemotherapy are reviewed and discussed. Results: The addition of a single-dose of rolapitant to combination 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone regimens provided increased protection against chemotherapyinduced nausea and vomiting, a benefit that encompassed the entire at-risk period investigated (0-120 hours after initiation of chemotherapy) in patients receiving highly or moderately emetogenic chemotherapy. Rolapitant was well tolerated by patients in these trials, with the overall frequency of treatment- related adverse events similar in patients receiving rolapitant (7.0%) and active placebo (6.3%). Conclusion: Rolapitant's favorable toxicity profile and lack of CYP3A4-related drug-drug interactions indicate that it would be a suitable treatment for older patients or those with multiple comorbidities, who are likely to be receiving a number of concomitant medications. Future studies should focus on the role of rolapitant in the control of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy, specific chemotherapy agents or high-dose chemotherapy and stem cell support.
MeSH term(s)	Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Humans ; Nausea/chemically induced ; Nausea/prevention & control ; Neoplasms/drug therapy ; Neurokinin-1 Receptor Antagonists/therapeutic use ; Spiro Compounds/therapeutic use ; Vomiting/chemically induced ; Vomiting/prevention & control
Chemical Substances	8-((1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4,5)decan-2-one ; Antineoplastic Agents ; Neurokinin-1 Receptor Antagonists ; Spiro Compounds
Language	English
Publishing date	2017
Publishing country	United Arab Emirates
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	2251879-4
ISSN	1876-1038 ; 1574-8871
ISSN (online)	1876-1038
ISSN	1574-8871
DOI	10.2174/1574887112666170406104854
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6436: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy.

Rapoport, Bernardo L / Anderson, Ronald

International journal of molecular sciences

2019 Volume 20, Issue 4

Abstract: Immunogenic cell death (ICD), which is triggered by exposure of tumor cells to a limited range of anticancer drugs, radiotherapy, and photodynamic therapy, represents a recent innovation in the revitalized and burgeoning field of oncoimmunnotherapy. ICD ... ...

Abstract	Immunogenic cell death (ICD), which is triggered by exposure of tumor cells to a limited range of anticancer drugs, radiotherapy, and photodynamic therapy, represents a recent innovation in the revitalized and burgeoning field of oncoimmunnotherapy. ICD results in the cellular redistribution and extracellular release of damage-associated molecular patterns (DAMPs), which have the potential to activate and restore tumor-targeted immune responses. Although a convincing body of evidence exists with respect to the antitumor efficacy of ICD in various experimental systems, especially murine models of experimental anticancer immunotherapy, evidence for the existence of ICD in the clinical setting is less compelling. Following overviews of hallmark developments, which have sparked the revival of interest in the field of oncoimmunotherapy, types of tumor cell death and the various DAMPs most prominently involved in the activation of antitumor immune responses, the remainder of this review is focused on strategies which may potentiate ICD in the clinical setting. These include identification of tumor- and host-related factors predictive of the efficacy of ICD, the clinical utility of combinatorial immunotherapeutic strategies, novel small molecule inducers of ICD, novel and repurposed small molecule immunostimulants, as well as the critical requirement for validated biomarkers in predicting the efficacy of ICD.
MeSH term(s)	Alarmins/metabolism ; Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Cell Death/drug effects ; Endoplasmic Reticulum Stress/drug effects ; Endoplasmic Reticulum Stress/radiation effects ; Humans ; Neoplasms/drug therapy ; Neoplasms/immunology ; Neoplasms/pathology ; Neoplasms/radiotherapy ; Radiotherapy
Chemical Substances	Alarmins ; Antineoplastic Agents
Language	English
Publishing date	2019-02-22
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms20040959
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma.

Kgokolo, Mahlatse C M / Malinga, Nonkululeko Z / Steel, Helen C / Meyer, Pieter W A / Smit, Teresa / Anderson, Ronald / Rapoport, Bernardo L

Translational oncology

2024 Volume 42, Page(s) 101867

Abstract: The current study compared the levels and possible associations between systemic soluble immune checkpoints (sICPs, n = 17) and a group of humoral modulators of immune suppressor cells (n = 7) in a cohort of patients with basal cell carcinoma (BCC, n = ... ...

Abstract	The current study compared the levels and possible associations between systemic soluble immune checkpoints (sICPs, n = 17) and a group of humoral modulators of immune suppressor cells (n = 7) in a cohort of patients with basal cell carcinoma (BCC, n = 40) and a group of healthy control subjects (n = 20). The seven humoral modulators of immunosuppressor cells were represented by the enzymes, arginase 1 and fibroblast activation protein (FAP), the chemokine, RANTES (CCL5) and the cytokines, interleukin-10 and transforming growth factor-β1 (TGF-β1), as well as the M2-type macrophage markers, soluble CD163 (sCD163) and sCD206. The plasma levels of six co-inhibitory sICPs, sCTLA-4, sLAG-3, sPD-1, sPD-L1, sTIM-3 and sPD-L2 were significantly elevated in the cohort of BCC patients (p<0.001-p<0.00001), while that of sBTLA was significantly decreased (p<0.006). Of the co-stimulatory sICPs, sCD27 and sGITR were significantly increased (p<0.0002 and p<0.0538) in the cohort of BCC patients, while the others were essentially comparable with those of the control participants; of the dual active sICPs, sHVEM was significantly elevated (p<0.00001) and TLR2 comparable with the control group. A correlation heat map revealed selective, strong associations of TGF-β1 with seven co-stimulatory (z = 0.618468-0.768131) and four co-inhibitory (z = 0.674040-0.808365) sICPs, as well as with sTLR2 (z = 0.696431). Notwithstanding the association of BCC with selective elevations in the levels of a large group of co-inhibitory sICPs, our novel findings also imply the probable involvement of TGF-β1 in driving immunosuppression in this malignancy, possibly via activation of regulatory T cells. Notably, these abnormalities were present in patients with either newly diagnosed or recurrent disease.
Language	English
Publishing date	2024-02-02
Publishing country	United States
Document type	Journal Article
ZDB-ID	2443840-6
ISSN	1936-5233
ISSN	1936-5233
DOI	10.1016/j.tranon.2023.101867
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Kategorien

Order via subito

Inter-library loan at ZB MED

Kategorien

Order via subito

Inter-library loan at ZB MED

Kategorien

Order via subito

Inter-library loan at ZB MED

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito